Recently, Associate professor Li Hong-yu from University of Arizona made a visit to CIB. He made a report named A Preclinical Case Study of Kinase Inhibitors for Cancer Targeted Therapy. The report was chaired by Prof. Sun Jian.

During the report, Dr. Li Hong-yu introduced the biological function and mechanism of transforming growth factor-β (TGF-β), and the methods that how to develop lead compounds inhibiting TGF-β and antineoplastic drugs by active compounds based on high throughput screening.　

Associate professor Li Hong-yu is from the College of Pharmacy, University of Arizona. He focused his research in development of new antineoplastic drugs. Also, he has published many papers in international renowned journals, including J. Med. Chem.，Angew. Chem. Int. Ed .etc.